Dr Michael English
With a group of others pioneered the first Excimer Laser used in Perth in the mid 90's. Michael is a fellow of the Royal College of Surgeons and the Royal Ausralian and New Zealand Collage of Ophthal-mologists. He is also a fellow of the Royal Collage of Ophthalmology (UK).
New IOL for Refractive Lens Exchange
The Synchrony IOL: Multifocal IOLs Beware?
June 15, 2006
· Analysis by: Sanjay Rao
· Analysis of: Physicians hopeful for dual-optic IOL
· Published at: www.eyeworld.org
While not yet FDA-approved, the Synchrony lens by Visiogen appears to be the newest accommodating lens to potentially receive approval. The Synchrony would be a competitor to current IOL options that restore near function such as Restor, Rezoom, and Crystalens. The Synchrony's dual-optic design makes it unique among accommodating IOLs and potentially confers some advantages over multifocal lenses (Restor, Rezoom) and single-optic accommodating lenses (Crystalens). First, the dual-optic design of the Synchrony allows recipients more potential for accommodation with less lens movement. Second, there is less potential for glare and halos with the Synchrony than with multifocal lenses because there are no different refractive zones. A significant downside however may be the fact that accommodation is less predictable with the Synchrony because it does rely on the individual patient's movement of the capsular bag.
The Synchrony is in Phase III clinical trials. There are several important issues that will determine how the Synchrony will compete against the currently available multifocal options.
The issue of predictability is a big one. With multifocal lenses, predictability has not been a major issue. Most surgeons feel fairly comfortable with what they can achieve using multifocal lenses. While far from perfect, surgeons can appropriately manage expectations when they know what the lenses can do and cannot do. With accommodating lenses, predictability is more of an issue. It has certainly been an issue with the Crystalens accommodating IOL, where the post-FDA approval results have not been as outstanding as the clinical trial data. It is unclear whether the Synchrony will have the same predictability issues, but the issue will certainly be an important factor in its success.
The second major issue will be surgeon acceptance. A large part of the successful market performance of the multifocals has been the fact that the lenses are easy to use. They are on lens platforms that surgeons are familiar with and do not require any significant change in technique. The Synchrony, because of its different design and size, may be intimidating to some surgeons because it will certainly require some minor changes in technique.
Posted 28 July 2010